Short Summary
Cyandia filed an authorized response opposing SAP’s Director Review Request, asserting that the PTAB’s institution decision was proper and that SAP’s arguments were waived. The patent owner relies on Sotera, Motorola, and Dell precedents and highlights Fintiv factors favoring denial.
Detailed Summary
In the authorized response to SAP America’s Director Review Request, Cyandia contends that the PTAB correctly applied the Sotera precedent and that SAP’s Sotera‑style stipulation fails to address overlapping system art already raised in the district court. The patent owner argues that SAP’s arguments are untimely, waived, and unsupported by record evidence, and that there is no panel split when compared with recent Dell and Motorola decisions. Emphasizing the holistic weighing of all six Fintiv factors, Cyandia asserts that discretionary denial of the review request is warranted, leaving the institution decision intact.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in SAP America, Inc. et al. vs Cyandia, Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Plaid Inc.vsSecure Authentication Technologies LLC et al.
Plaid Inc. has filed an IPR petition challenging U.S. Patent 11,315,090, asserting that its ten claims on automated multi‑factor authentication are anticipated or obvious over earlier patents and public disclosures.
LG Energy Solution, Ltd.vsMolecular Rebar Design, LLC
LG Energy Solution successfully petitioned to institute an IPR against Molecular Rebar Design, LLC's battery patent (8968924). The Board found sufficient evidence of obviousness over combinations of prior art references like Ohata and Kavan. This decision allows the challenge to proceed to a full trial phase at the PTAB.
Micron Technology, Inc. et al.vsYangtze Memory Technologies Company, Ltd.
The PTAB denied Micron's IPR petition against Yangtze Memory because the patent owner had successfully filed a statutory disclaimer covering all challenged claims related to 3D memory devices.
Accord BioPharma, Inc. et al.vsJanssen Biotech, Inc. et al.
Accord BioPharma petitions the PTAB to invalidate Janssen’s golimumab patent (US 11,041,020) on the basis that the claims are anticipated and obvious over the company’s own clinical‑trial protocol and other prior art.
Coretronic CorporationvsMaxell, LTD.
Coretronic and Optoma have filed an IPR petition seeking to invalidate 19 claims of Maxell’s U.S. Patent 8,593,580 covering a projection-type display apparatus. The petition relies on eight obviousness grounds combining prior art such as Ishino, Erchak, Li ’415, Uchiyama, and Bakker, and argues that discretionary denial factors do not apply.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.